Advair
Author: Chris Mulligan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). The drug has anti-inflammatory and bronchodilatory effects on patients with asthma. It is administered twice daily through a dry powder inhaler device called Advair Diskus, or a pressurized metered-dose inhaler device known as Advair hydrofluoroalkane (HFA).
Twice-daily Advair was the first ICS/LABA combination to launch and quickly became the gold standard in its class and across the asthma and COPD markets. It was first launched for asthma in the UK in 1999 and was rolled out in the rest of Europe in 2000–01 and in the US in 2001. It became available in Japan in 2007. While the majority of sales are for asthma, the drug is a blockbuster for COPD as well.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Advair : Chronic obstructive pulmonary disease (COPD)
16 Advair : Asthma
LIST OF FIGURES
8 Figure 1: Advair for COPD – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Advair for COPD
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Advair for COPD
13 Figure 4: Advair sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
28 Figure 5: Advair for asthma – SWOT analysis
29 Figure 6: Datamonitor Healthcare’s drug assessment summary of Advair in asthma
30 Figure 7: Datamonitor Healthcare’s drug assessment summary of Advair in asthma
33 Figure 8: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Advair drug profile
7 Table 2: Advair Phase III data in COPD
14 Table 3: Advair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
16 Table 4: Advair drug profile
18 Table 5: Advair Diskus pivotal trial data in asthma
21 Table 6: Advair HFA pivotal trial data in asthma
23 Table 7: Advair late-phase trial data in asthma
34 Table 8: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Duaklir Pressair 
Sign up to the